Pyxis Oncology, Inc.
- Open
- 2.49
- Day high
- 3.40
- Day low
- 2.45
- Prev close
- 2.86
- Volume
- 7.0M
- Mkt cap
- $184M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 5.9
- P/S
- 13.3
- Yield
- —
- Per share
- —
Pyxis Oncology, Inc. (PYXS) is a Healthcare company listed on NASDAQ. The stock is up 179% over the past year.
Pyxis Oncology, Inc. (PYXS) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PYXS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 14, 2026 | $-0.35 | $-0.37 | -5.7% | — | — |
| Mar 23, 2026 | $-0.35 | $-0.29 | +17.1% | $11M | +8730.4% |
| Aug 14, 2025 | $-0.36 | $-0.30 | +16.7% | $3M | — |
| May 15, 2025 | $-0.29 | $-0.35 | -20.7% | — | — |
| Mar 18, 2025 | $-0.33 | $-0.32 | +3.0% | $3M | — |
| Aug 14, 2024 | $-0.33 | $-0.29 | +12.1% | — | — |
| Mar 21, 2024 | $-0.49 | $-0.33 | +32.7% | $3M | +1911.8% |
| Aug 11, 2023 | $-0.66 | $-0.41 | +37.9% | — | — |
| May 11, 2023 | $-0.84 | $-0.54 | +35.7% | — | — |
| Mar 22, 2023 | $-0.85 | $-1.04 | -22.4% | — | — |
| Nov 1, 2022 | $-0.76 | $-0.85 | -11.8% | — | — |
| Aug 15, 2022 | $-0.68 | $-0.79 | -16.2% | — | — |
PYXS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 25, 2026 | Metzger Michael Adirector | Grant | 45,867 | $1.36 |
| Mar 25, 2026 | FLAVIN JOHN Ldirector | Grant | 45,867 | $1.36 |
| Mar 25, 2026 | Dupont Jakobdirector | Grant | 45,867 | $1.36 |
| Mar 25, 2026 | Wadhane Jitendraofficer: Prin Fin & Acct Officer | Grant | 109,461 | — |
| Mar 25, 2026 | Wadhane Jitendraofficer: Prin Fin & Acct Officer | Grant | 262,635 | $1.36 |
| Mar 25, 2026 | HUMPHREY RACHELdirector | Sell | 13,896 | $1.03 |
| Mar 25, 2026 | HUMPHREY RACHELdirector | Sell | 200 | $0.97 |
| Mar 25, 2026 | HUMPHREY RACHELdirector | Sell | 1,400 | $0.97 |
| Mar 25, 2026 | Palani Santhoshdirector | Grant | 45,867 | $1.36 |
| Mar 25, 2026 | HUMPHREY RACHELdirector | Grant | 45,867 | $1.36 |
| Mar 25, 2026 | Cline Darren Sdirector | Grant | 45,867 | $1.36 |
| Mar 25, 2026 | Lewis-Hall Freda Cdirector | Grant | 45,867 | $1.36 |
| Feb 5, 2026 | Civik Thomasdirector, officer: Interim CEO | Grant | 690,131 | $1.49 |
| Apr 2, 2025 | FLAVIN JOHN Ldirector | Grant | 36,979 | $0.98 |
| Apr 2, 2025 | Sullivan Laradirector, officer: President ,CEO & CMO | Grant | 918,308 | $0.98 |
Source: PYXS SEC Form 4 filings, latest Mar 25, 2026. For informational purposes only — not investment advice.
See the full PYXS insider & 13F page →Pyxis Oncology, Inc. company profile
Overview
Pyxis Oncology, Inc. (NASDAQ:PYXS) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Cambridge, Massachusetts. The company went public in October 2021 and focuses on developing innovative cancer therapies through two primary technological approaches: immune-oncology treatments and antibody drug conjugates. As a preclinical company, Pyxis is in the early stages of drug development, with its product candidates still undergoing laboratory and early clinical testing before potentially advancing to human trials and eventual commercialization.
Business
Pyxis Oncology operates in the biotechnology sector, specifically focusing on oncology drug development. The company develops cancer treatments using two distinct but complementary approaches that represent cutting-edge areas of cancer research. The first approach involves immune-oncology therapies, which work by harnessing and enhancing the body's own immune system to fight cancer cells. Pyxis's lead immune-oncology candidates include PYX-106, a fully human antibody that targets a protein called siglec-15, which is found on certain immune cells and can suppress anti-tumor immune responses. By blocking siglec-15, PYX-106 aims to unleash the immune system's ability to attack cancer cells. This therapy is being developed for thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, and other solid tumors. The company also has PYX-102, another immune-therapeutic designed for solid tumor treatment. The second approach utilizes antibody drug conjugates (ADCs), which are sophisticated cancer treatments that combine the targeting precision of antibodies with the cell-killing power of chemotherapy drugs. ADCs work like guided missiles - the antibody portion seeks out and binds to specific proteins found on cancer cells, then delivers a highly potent chemotherapy payload directly to the tumor while sparing healthy cells. Pyxis has three ADC candidates: PYX-201 for non-small cell lung cancer, breast cancer, and other solid tumors; PYX-202 for small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203 for blood cancers including acute myeloid leukemia and myelodysplastic syndrome. Since the company is in preclinical stages, revenue generation is minimal and primarily comes from potential research collaborations or licensing arrangements rather than product sales.
Competitive moat
Pyxis Oncology's competitive moat is relatively narrow, as is typical for preclinical-stage biotechnology companies. The company's primary competitive advantages lie in its novel target selection and proprietary technology platforms. The siglec-15 target for PYX-106 represents a potentially differentiated approach in immune-oncology, as this target is less crowded than more established checkpoint inhibitors like PD-1 or PD-L1. However, the strength of this moat depends entirely on clinical validation, which remains unproven. The company's ADC platform may offer some competitive advantages through proprietary linker technology and payload selection, but the ADC space is highly competitive with established players like Seattle Genetics (now Seagen), Roche/Genentech, and AstraZeneca having significant head starts and deeper resources. Large pharmaceutical companies have substantial advantages in terms of manufacturing capabilities, regulatory expertise, commercial infrastructure, and financial resources to conduct large-scale clinical trials. Intellectual property protection provides some defensive moat, but patent landscapes in biotechnology are complex and often subject to challenges. The company's preclinical stage means it lacks the most important moat in pharmaceuticals: proven clinical efficacy and regulatory approval. Without approved products, Pyxis faces significant execution risk and depends heavily on successful clinical development, which has historically high failure rates in oncology. The competitive threats are substantial, including well-funded biotechnology companies working on similar targets, large pharmaceutical companies with competing programs, and the potential for breakthrough therapies in adjacent areas that could reduce market opportunity. The company's survival and success depend more on execution excellence and clinical success rather than sustainable competitive advantages at this stage.
Risks & safety
The margin of safety for Pyxis Oncology is concerning, reflecting the high-risk nature of preclinical biotechnology investments. • Cash position and burn rate: With only $12.8 million in cash and short-term investments as of Q1 2025, down from $19.5 million in Q4 2024, the company faces immediate funding pressures. Operating cash flow burn of approximately $58 million annually means current cash provides less than one quarter of runway. • Debt and solvency: Low debt-to-equity ratio of 0.19 indicates minimal debt burden, but the company's negative $21+ million quarterly losses and accelerating cash burn create significant solvency risk without additional funding. • Valuation metrics: Trading at 0.58x book value suggests potential asset value, but negative earnings make traditional valuation metrics less meaningful. The company's $84 million market capitalization is below its net assets, indicating market skepticism. • Financial runway: Based on current burn rates, the company likely needs to raise additional capital within the next 6-12 months to continue operations, creating significant dilution risk for existing shareholders. • Clinical stage risk: As a preclinical company with no approved products or meaningful revenue, the investment carries binary risk profiles typical of early-stage biotech, where clinical failures can result in near-total value destruction.
Recent development
Based on the available financial data, Pyxis Oncology has been primarily focused on advancing its preclinical pipeline while managing cash resources. The company generated $16.1 million in revenue during 2024, representing a significant increase from zero revenue in previous years, likely indicating progress in research collaborations or licensing arrangements. This suggests the company may be pursuing partnership strategies to validate its technology platforms and generate non-dilutive funding. The company's cash position has declined substantially from $179 million at the end of 2022 to just $12.8 million by Q1 2025, reflecting the intensive capital requirements of drug development. The acceleration in cash burn from approximately $70 million in 2023 to $58 million in 2024, despite some revenue generation, indicates increased research and development activities as the company advances its pipeline toward clinical trials. The financial trajectory suggests Pyxis is approaching critical inflection points where it will need to demonstrate clinical proof-of-concept to attract additional investment or partnership interest. The company's ability to generate some revenue in 2024 while maintaining a focused pipeline approach indicates management is actively pursuing value-creating partnerships and collaborations to extend runway and validate its therapeutic approaches. However, the rapid cash depletion suggests the company is likely preparing for significant clinical milestones or seeking strategic alternatives to continue operations.
PYXS company profile · for informational purposes only — not investment advice.
Track PYXS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free